Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Short-term Activity Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-28), 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
An examination of short-term operating activity ratios reveals several noteworthy trends between 2021 and 2025. Generally, efficiency metrics related to inventory and receivables demonstrate a weakening trend, while payables management remains relatively stable. A significant fluctuation is observed in working capital turnover, particularly in the later years of the period.
- Inventory Management
- Inventory turnover consistently declined from 2.87 in 2021 to 2.13 in 2025. This suggests a growing inefficiency in managing inventory levels, potentially indicating overstocking or slower sales. Correspondingly, the average inventory processing period lengthened from 127 days in 2021 to 171 days in 2025, reinforcing the observation of slower inventory movement.
- Receivables Management
- Receivables turnover exhibited a gradual decrease from 6.14 in 2021 to 5.48 in 2025. This indicates a lengthening of the time it takes to collect on credit sales. The average receivable collection period increased from 59 days in 2021 to 67 days in 2025, confirming this trend. While the decrease is not dramatic year-over-year, the cumulative effect suggests a potential deterioration in the effectiveness of credit and collection policies.
- Payables Management
- Payables turnover remained relatively stable throughout the period, fluctuating between 2.52 and 2.76. The average payables payment period showed minor variations, increasing from 135 days in 2021 to 145 days in 2025. This suggests consistent management of supplier credit terms.
- Working Capital Turnover
- Working capital turnover experienced substantial volatility. It was not reported for 2022, but increased significantly from 11.81 in 2023 to 15.94 in 2024, and then dramatically to 62.88 in 2025. This large increase in 2025 suggests a substantial improvement in the efficiency with which working capital is used to generate sales, or potentially a significant reduction in working capital investment. Further investigation is warranted to understand the drivers behind this substantial change.
- Operating and Cash Cycles
- Both the operating cycle and the cash conversion cycle lengthened consistently throughout the period. The operating cycle increased from 186 days in 2021 to 238 days in 2025, reflecting the combined effect of slower inventory turnover and receivable collection. The cash conversion cycle increased from 51 days in 2021 to 93 days in 2025, indicating a longer period between paying suppliers and collecting cash from customers. This trend suggests a growing need for efficient working capital management.
AI Ask an analyst for more
Turnover Ratios
Average No. Days
Inventory Turnover
| Dec 28, 2025 | Dec 29, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Cost of products sold | 30,256) | 27,471) | 26,553) | 31,089) | 29,855) | |
| Inventories | 14,191) | 12,444) | 11,181) | 12,483) | 10,387) | |
| Short-term Activity Ratio | ||||||
| Inventory turnover1 | 2.13 | 2.21 | 2.37 | 2.49 | 2.87 | |
| Benchmarks | ||||||
| Inventory Turnover, Competitors2 | ||||||
| AbbVie Inc. | 3.68 | 4.04 | 4.98 | 4.87 | 5.58 | |
| Amgen Inc. | 1.93 | 1.84 | 0.89 | 1.30 | 1.58 | |
| Bristol-Myers Squibb Co. | 5.18 | 5.46 | 4.02 | 4.33 | 4.74 | |
| Danaher Corp. | 4.04 | 4.15 | 3.80 | 4.03 | 4.16 | |
| Eli Lilly & Co. | 0.80 | 1.11 | 1.23 | 1.54 | 1.88 | |
| Gilead Sciences Inc. | 3.51 | 3.66 | 3.64 | 3.75 | 4.08 | |
| Merck & Co. Inc. | 2.46 | 2.49 | 2.54 | 2.95 | 2.29 | |
| Pfizer Inc. | 1.51 | 1.65 | 2.45 | 3.82 | 3.40 | |
| Regeneron Pharmaceuticals Inc. | 0.66 | 0.64 | 0.70 | 0.65 | 1.25 | |
| Thermo Fisher Scientific Inc. | 4.85 | 5.06 | 5.06 | 4.60 | 3.88 | |
| Vertex Pharmaceuticals Inc. | 0.98 | 1.27 | 1.71 | 2.35 | 2.56 | |
| Inventory Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 2.23 | 2.46 | 2.55 | 3.06 | 3.11 | |
| Inventory Turnover, Industry | ||||||
| Health Care | 7.55 | 7.56 | 7.36 | 7.85 | 7.90 | |
Based on: 10-K (reporting date: 2025-12-28), 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Inventory turnover = Cost of products sold ÷ Inventories
= 30,256 ÷ 14,191 = 2.13
2 Click competitor name to see calculations.
An analysis of short-term operating activity reveals a consistent decline in inventory turnover over the five-year period. While cost of products sold demonstrates some fluctuation, inventories have generally increased, contributing to the observed trend.
- Inventory Turnover Trend
- The inventory turnover ratio decreased steadily from 2.87 in 2021 to 2.13 in 2025. This indicates a lengthening of the time it takes to sell inventory. The most significant decline occurred between 2021 and 2022, dropping to 2.49, and the rate of decline has slowed slightly in more recent years, but remains consistently negative.
- Cost of Products Sold
- Cost of products sold increased from US$29,855 million in 2021 to US$31,089 million in 2022, then decreased to US$26,553 million in 2023. A modest increase was observed in 2024, reaching US$27,471 million, followed by a further increase to US$30,256 million in 2025. These fluctuations in cost of goods sold do not appear to fully offset the increases in inventory levels.
- Inventory Levels
- Inventories rose from US$10,387 million in 2021 to US$12,483 million in 2022, representing a substantial increase. While inventories decreased slightly to US$11,181 million in 2023, they subsequently increased again, reaching US$12,444 million in 2024 and US$14,191 million in 2025. This consistent growth in inventory, coupled with the fluctuations in cost of products sold, directly contributes to the declining inventory turnover ratio.
The combined effect of increasing inventory levels and fluctuating cost of products sold suggests a potential slowdown in the efficiency of inventory management. Further investigation may be warranted to understand the reasons behind the increasing inventory and to assess the impact on overall profitability and working capital.
AI Ask an analyst for more
Receivables Turnover
| Dec 28, 2025 | Dec 29, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Sales to customers | 94,193) | 88,821) | 85,159) | 94,943) | 93,775) | |
| Accounts receivable trade, less allowances | 17,178) | 14,842) | 14,873) | 16,160) | 15,283) | |
| Short-term Activity Ratio | ||||||
| Receivables turnover1 | 5.48 | 5.98 | 5.73 | 5.88 | 6.14 | |
| Benchmarks | ||||||
| Receivables Turnover, Competitors2 | ||||||
| AbbVie Inc. | 4.86 | 5.16 | 4.87 | 5.16 | 5.63 | |
| Amgen Inc. | 3.67 | 4.72 | 3.70 | 4.46 | 4.96 | |
| Bristol-Myers Squibb Co. | 4.87 | 5.19 | 4.93 | 5.48 | 5.65 | |
| Danaher Corp. | 6.28 | 6.75 | 6.09 | 6.40 | 6.36 | |
| Eli Lilly & Co. | 3.67 | 4.09 | 3.75 | 4.14 | 4.24 | |
| Gilead Sciences Inc. | 5.89 | 6.47 | 5.78 | 5.65 | 6.01 | |
| Merck & Co. Inc. | 5.52 | 6.24 | 5.81 | 6.27 | 5.28 | |
| Pfizer Inc. | 5.27 | 5.55 | 5.33 | 9.24 | 7.16 | |
| Regeneron Pharmaceuticals Inc. | 2.50 | 2.29 | 2.31 | 2.28 | 2.66 | |
| Thermo Fisher Scientific Inc. | 5.01 | 5.23 | 5.21 | 5.53 | 4.92 | |
| Vertex Pharmaceuticals Inc. | 5.85 | 6.85 | 6.31 | 6.19 | 6.66 | |
| Receivables Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 4.79 | 5.26 | 4.96 | 5.76 | 5.54 | |
| Receivables Turnover, Industry | ||||||
| Health Care | 7.58 | 7.97 | 7.66 | 8.22 | 8.00 | |
Based on: 10-K (reporting date: 2025-12-28), 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Receivables turnover = Sales to customers ÷ Accounts receivable trade, less allowances
= 94,193 ÷ 17,178 = 5.48
2 Click competitor name to see calculations.
The receivables turnover ratio exhibited a generally declining trend over the five-year period, with some fluctuation. Sales to customers also demonstrated variability, impacting the interpretation of the receivables turnover. A detailed examination of the ratio and its components follows.
- Receivables Turnover Trend
- The receivables turnover ratio decreased from 6.14 in 2021 to 5.88 in 2022, representing a slight reduction in efficiency of collecting receivables. It continued to decline to 5.73 in 2023, indicating a further slowdown in the rate at which the company converts its receivables into cash. A modest increase was observed in 2024, with the ratio rising to 5.98. However, this positive movement was reversed in 2025, as the ratio decreased to 5.48, reaching its lowest point over the observed period.
- Sales Impact
- Sales to customers remained relatively stable between 2021 and 2022, increasing from US$93,775 million to US$94,943 million. A significant decrease in sales occurred in 2023, falling to US$85,159 million, which likely contributed to the lower receivables turnover observed in that year. Sales partially recovered in 2024 to US$88,821 million and then increased substantially in 2025 to US$94,193 million. Despite the sales increase in 2025, the receivables turnover ratio still declined, suggesting a potential issue with the collection process or a change in credit terms.
- Accounts Receivable Levels
- Accounts receivable trade, less allowances, increased from US$15,283 million in 2021 to US$16,160 million in 2022. It then decreased to US$14,873 million in 2023, aligning with the decrease in sales. A slight decrease was noted in 2024 to US$14,842 million, followed by a substantial increase to US$17,178 million in 2025. The increase in accounts receivable in 2025, coupled with a lower receivables turnover, suggests that the company is taking longer to collect payments, potentially indicating a need to review credit policies or collection efforts.
In summary, while sales experienced fluctuations, the consistent downward trend in the receivables turnover ratio, particularly the decline in 2025 despite increased sales, warrants further investigation. The increasing level of accounts receivable in the most recent year, combined with the lower turnover, suggests a potential weakening in the efficiency of managing credit and collections.
AI Ask an analyst for more
Payables Turnover
| Dec 28, 2025 | Dec 29, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Cost of products sold | 30,256) | 27,471) | 26,553) | 31,089) | 29,855) | |
| Accounts payable | 11,991) | 10,311) | 9,632) | 11,703) | 11,055) | |
| Short-term Activity Ratio | ||||||
| Payables turnover1 | 2.52 | 2.66 | 2.76 | 2.66 | 2.70 | |
| Benchmarks | ||||||
| Payables Turnover, Competitors2 | ||||||
| AbbVie Inc. | 5.07 | 5.74 | 5.54 | 5.94 | 6.05 | |
| Amgen Inc. | 5.09 | 6.74 | 5.32 | 4.08 | 4.72 | |
| Bristol-Myers Squibb Co. | 3.90 | 3.88 | 3.28 | 3.33 | 3.37 | |
| Danaher Corp. | 5.45 | 5.52 | 5.58 | 5.45 | 4.48 | |
| Eli Lilly & Co. | 2.05 | 2.61 | 2.73 | 3.43 | 4.38 | |
| Gilead Sciences Inc. | 8.72 | 7.50 | 11.81 | 6.25 | 9.36 | |
| Merck & Co. Inc. | 3.72 | 3.72 | 4.11 | 4.08 | 2.96 | |
| Pfizer Inc. | 3.07 | 3.17 | 3.72 | 5.04 | 5.53 | |
| Regeneron Pharmaceuticals Inc. | 2.24 | 2.50 | 2.99 | 2.65 | 4.32 | |
| Thermo Fisher Scientific Inc. | 7.27 | 8.18 | 8.97 | 7.67 | 6.83 | |
| Vertex Pharmaceuticals Inc. | 3.58 | 3.71 | 3.46 | 3.55 | 4.64 | |
| Payables Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 3.72 | 4.08 | 4.25 | 4.28 | 4.23 | |
| Payables Turnover, Industry | ||||||
| Health Care | 6.15 | 6.10 | 5.97 | 5.79 | 5.84 | |
Based on: 10-K (reporting date: 2025-12-28), 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Payables turnover = Cost of products sold ÷ Accounts payable
= 30,256 ÷ 11,991 = 2.52
2 Click competitor name to see calculations.
The accounts payable turnover ratio exhibits a relatively stable pattern over the five-year period, with minor fluctuations. While generally consistent, a slight downward trend is observable towards the end of the analyzed timeframe.
- Payables Turnover Trend
- The payables turnover ratio began at 2.70 in 2021, decreased slightly to 2.66 in 2022, and then increased to 2.76 in 2023. It subsequently decreased again to 2.66 in 2024, and further declined to 2.52 in 2025. This suggests a modest lengthening in the time it takes to pay suppliers towards the end of the period.
- Relationship to Cost of Products Sold
- Cost of products sold experienced an increase from 2021 to 2022, followed by a decrease in 2023, and then increases in both 2024 and 2025. Accounts payable generally tracked this pattern, increasing from 2021 to 2022, decreasing in 2023, and increasing again in 2024 and 2025. The relatively consistent payables turnover ratio, despite these fluctuations in both cost of products sold and accounts payable, indicates a consistent payment policy.
- Recent Performance
- The decrease in the payables turnover ratio in 2025, to 2.52, represents the lowest value observed during the analyzed period. This could indicate a deliberate strategy to extend payment terms with suppliers, potentially to improve cash flow, or it could be a result of changes in supplier relationships or purchasing practices. Further investigation would be required to determine the underlying cause.
Overall, the accounts payable turnover ratio demonstrates a generally stable performance with a slight downward trend in the most recent year. The relationship between the ratio, cost of products sold, and accounts payable suggests a consistent, though potentially evolving, approach to supplier payments.
AI Ask an analyst for more
Working Capital Turnover
| Dec 28, 2025 | Dec 29, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Current assets | 55,624) | 55,893) | 53,495) | 55,294) | 60,979) | |
| Less: Current liabilities | 54,126) | 50,321) | 46,282) | 55,802) | 45,226) | |
| Working capital | 1,498) | 5,572) | 7,213) | (508) | 15,753) | |
| Sales to customers | 94,193) | 88,821) | 85,159) | 94,943) | 93,775) | |
| Short-term Activity Ratio | ||||||
| Working capital turnover1 | 62.88 | 15.94 | 11.81 | — | 5.95 | |
| Benchmarks | ||||||
| Working Capital Turnover, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | 9.85 | 5.40 | 2.25 | 3.82 | 3.37 | |
| Bristol-Myers Squibb Co. | 7.83 | 7.79 | 4.60 | 8.30 | 3.95 | |
| Danaher Corp. | 4.13 | 8.85 | 4.22 | 4.20 | 8.40 | |
| Eli Lilly & Co. | 3.19 | 10.32 | — | 31.84 | 8.33 | |
| Gilead Sciences Inc. | 4.43 | 3.99 | 5.61 | 8.42 | 8.54 | |
| Merck & Co. Inc. | 4.28 | 6.19 | 9.29 | 5.16 | 7.62 | |
| Pfizer Inc. | 10.58 | 8.64 | — | 11.09 | 4.83 | |
| Regeneron Pharmaceuticals Inc. | 1.05 | 0.97 | 0.82 | 0.96 | 1.59 | |
| Thermo Fisher Scientific Inc. | 3.30 | 4.87 | 4.05 | 5.46 | 5.87 | |
| Vertex Pharmaceuticals Inc. | 1.64 | 1.83 | 0.93 | 0.85 | 1.02 | |
| Working Capital Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 6.50 | 7.86 | 6.68 | 7.25 | 5.87 | |
| Working Capital Turnover, Industry | ||||||
| Health Care | 11.25 | 12.35 | 10.99 | 11.30 | 8.57 | |
Based on: 10-K (reporting date: 2025-12-28), 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Working capital turnover = Sales to customers ÷ Working capital
= 94,193 ÷ 1,498 = 62.88
2 Click competitor name to see calculations.
The working capital turnover ratio exhibits significant fluctuations over the observed period. Initial values indicate a relatively stable level, followed by substantial volatility and a marked increase in later years.
- Working Capital
- Working capital demonstrates considerable variability. A substantial decrease is noted between 2021 and 2022, resulting in a negative value in 2022. Subsequent years show recovery, with values increasing through 2023, decreasing in 2024, and then declining sharply in 2025.
- Sales to Customers
- Sales to customers remained relatively consistent between 2021 and 2023, with a slight decrease observed in 2023. A moderate increase occurred in 2024, followed by a return to levels comparable to those in 2021 and 2022 in 2025.
- Working Capital Turnover
- The working capital turnover ratio was 5.95 in 2021. The ratio is unavailable for 2022, coinciding with the negative working capital position. A substantial increase to 11.81 is observed in 2023, which further accelerates to 15.94 in 2024. The most significant change occurs between 2024 and 2025, with the ratio increasing dramatically to 62.88. This final increase suggests a significantly more efficient utilization of working capital in relation to sales, or potentially a substantial reduction in working capital relative to sales.
The large fluctuations in the working capital turnover ratio are closely linked to the changes in working capital. The negative working capital in 2022 prevents calculation of the ratio for that year. The increasing trend in the ratio from 2023 to 2025, particularly the pronounced increase in 2025, warrants further investigation to determine the underlying drivers, such as changes in inventory management, accounts receivable collection periods, or accounts payable payment terms.
AI Ask an analyst for more
Average Inventory Processing Period
| Dec 28, 2025 | Dec 29, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Inventory turnover | 2.13 | 2.21 | 2.37 | 2.49 | 2.87 | |
| Short-term Activity Ratio (no. days) | ||||||
| Average inventory processing period1 | 171 | 165 | 154 | 147 | 127 | |
| Benchmarks (no. days) | ||||||
| Average Inventory Processing Period, Competitors2 | ||||||
| AbbVie Inc. | 99 | 90 | 73 | 75 | 65 | |
| Amgen Inc. | 189 | 199 | 411 | 281 | 231 | |
| Bristol-Myers Squibb Co. | 70 | 67 | 91 | 84 | 77 | |
| Danaher Corp. | 90 | 88 | 96 | 91 | 88 | |
| Eli Lilly & Co. | 454 | 329 | 298 | 237 | 194 | |
| Gilead Sciences Inc. | 104 | 100 | 100 | 97 | 89 | |
| Merck & Co. Inc. | 148 | 147 | 144 | 124 | 159 | |
| Pfizer Inc. | 242 | 222 | 149 | 95 | 107 | |
| Regeneron Pharmaceuticals Inc. | 556 | 572 | 519 | 562 | 292 | |
| Thermo Fisher Scientific Inc. | 75 | 72 | 72 | 79 | 94 | |
| Vertex Pharmaceuticals Inc. | 373 | 287 | 214 | 156 | 143 | |
| Average Inventory Processing Period, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 164 | 149 | 143 | 119 | 117 | |
| Average Inventory Processing Period, Industry | ||||||
| Health Care | 48 | 48 | 50 | 46 | 46 | |
Based on: 10-K (reporting date: 2025-12-28), 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 2.13 = 171
2 Click competitor name to see calculations.
An examination of the provided financial information reveals a consistent trend in inventory management metrics over the five-year period. Specifically, inventory turnover decreases while the average inventory processing period increases annually.
- Inventory Turnover
- Inventory turnover decreased from 2.87 in 2021 to 2.13 in 2025. This represents a cumulative decline of approximately 26%. The rate of decline appears to be slowing, with smaller decreases observed in later years compared to the initial drop from 2021 to 2022.
- Average Inventory Processing Period
- The average inventory processing period lengthened from 127 days in 2021 to 171 days in 2025, an increase of 44 days. Similar to the inventory turnover ratio, the pace of increase in the processing period appears to moderate over time. The largest increase occurred between 2021 and 2022, adding 20 days to the processing period. Subsequent annual increases were smaller, ranging from 7 to 11 days.
The observed trends suggest a growing inefficiency in inventory management. A declining inventory turnover ratio, coupled with an increasing average inventory processing period, indicates that the entity is taking longer to sell its inventory. This could be attributable to several factors, including shifts in demand, changes in inventory management strategies, or potential issues with product obsolescence. Further investigation would be required to determine the underlying causes and assess the potential impact on profitability and working capital.
AI Ask an analyst for more
Average Receivable Collection Period
| Dec 28, 2025 | Dec 29, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Receivables turnover | 5.48 | 5.98 | 5.73 | 5.88 | 6.14 | |
| Short-term Activity Ratio (no. days) | ||||||
| Average receivable collection period1 | 67 | 61 | 64 | 62 | 59 | |
| Benchmarks (no. days) | ||||||
| Average Receivable Collection Period, Competitors2 | ||||||
| AbbVie Inc. | 75 | 71 | 75 | 71 | 65 | |
| Amgen Inc. | 99 | 77 | 99 | 82 | 74 | |
| Bristol-Myers Squibb Co. | 75 | 70 | 74 | 67 | 65 | |
| Danaher Corp. | 58 | 54 | 60 | 57 | 57 | |
| Eli Lilly & Co. | 99 | 89 | 97 | 88 | 86 | |
| Gilead Sciences Inc. | 62 | 56 | 63 | 65 | 61 | |
| Merck & Co. Inc. | 66 | 58 | 63 | 58 | 69 | |
| Pfizer Inc. | 69 | 66 | 69 | 40 | 51 | |
| Regeneron Pharmaceuticals Inc. | 146 | 160 | 158 | 160 | 137 | |
| Thermo Fisher Scientific Inc. | 73 | 70 | 70 | 66 | 74 | |
| Vertex Pharmaceuticals Inc. | 62 | 53 | 58 | 59 | 55 | |
| Average Receivable Collection Period, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 76 | 69 | 74 | 63 | 66 | |
| Average Receivable Collection Period, Industry | ||||||
| Health Care | 48 | 46 | 48 | 44 | 46 | |
Based on: 10-K (reporting date: 2025-12-28), 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 5.48 = 67
2 Click competitor name to see calculations.
An examination of short-term activity ratios reveals a generally increasing trend in the average receivable collection period, coupled with a fluctuating receivables turnover ratio over the five-year period. These movements suggest potential shifts in the efficiency of credit and collection processes.
- Receivables Turnover
- The receivables turnover ratio decreased from 6.14 in 2021 to 5.88 in 2022, and continued a slight downward trend to 5.73 in 2023. A modest increase was noted in 2024, with the ratio reaching 5.98, but it subsequently declined to 5.48 in 2025. This indicates a fluctuating ability to convert receivables into cash, with the most recent year showing the lowest turnover rate within the observed period.
- Average Receivable Collection Period
- The average receivable collection period exhibited an increasing trend over the period. Starting at 59 days in 2021, it rose to 62 days in 2022 and 64 days in 2023. A slight decrease to 61 days was observed in 2024, but the period lengthened again to 67 days in 2025. This suggests a lengthening of the time required to collect on credit sales, potentially indicating a need to review credit policies or collection procedures.
- Relationship between Ratios
- The inverse relationship between the receivables turnover ratio and the average collection period is apparent. As the turnover ratio decreased, the collection period generally increased, and vice versa. The decline in turnover and the corresponding increase in the collection period in 2025 warrant further investigation to determine the underlying causes, such as changes in customer payment behavior, credit terms, or the quality of receivables.
Overall, the observed trends suggest a potential weakening in the efficiency of managing accounts receivable. Continued monitoring of these ratios, alongside a detailed analysis of the components of accounts receivable, is recommended.
AI Ask an analyst for more
Operating Cycle
| Dec 28, 2025 | Dec 29, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Average inventory processing period | 171 | 165 | 154 | 147 | 127 | |
| Average receivable collection period | 67 | 61 | 64 | 62 | 59 | |
| Short-term Activity Ratio | ||||||
| Operating cycle1 | 238 | 226 | 218 | 209 | 186 | |
| Benchmarks | ||||||
| Operating Cycle, Competitors2 | ||||||
| AbbVie Inc. | 174 | 161 | 148 | 146 | 130 | |
| Amgen Inc. | 288 | 276 | 510 | 363 | 305 | |
| Bristol-Myers Squibb Co. | 145 | 137 | 165 | 151 | 142 | |
| Danaher Corp. | 148 | 142 | 156 | 148 | 145 | |
| Eli Lilly & Co. | 553 | 418 | 395 | 325 | 280 | |
| Gilead Sciences Inc. | 166 | 156 | 163 | 162 | 150 | |
| Merck & Co. Inc. | 214 | 205 | 207 | 182 | 228 | |
| Pfizer Inc. | 311 | 288 | 218 | 135 | 158 | |
| Regeneron Pharmaceuticals Inc. | 702 | 732 | 677 | 722 | 429 | |
| Thermo Fisher Scientific Inc. | 148 | 142 | 142 | 145 | 168 | |
| Vertex Pharmaceuticals Inc. | 435 | 340 | 272 | 215 | 198 | |
| Operating Cycle, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 240 | 218 | 217 | 182 | 183 | |
| Operating Cycle, Industry | ||||||
| Health Care | 96 | 94 | 98 | 90 | 92 | |
Based on: 10-K (reporting date: 2025-12-28), 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 171 + 67 = 238
2 Click competitor name to see calculations.
An examination of the short-term operating activity reveals consistent increases in the components of the operating cycle over the five-year period. The average inventory processing period, average receivable collection period, and consequently, the operating cycle itself, all demonstrate upward trends.
- Average Inventory Processing Period
- The average inventory processing period has exhibited a steady increase, rising from 127 days in 2021 to 171 days in 2025. This indicates a lengthening time required to convert raw materials into finished goods and ultimately sell them. The increase suggests potential inefficiencies in inventory management, slower sales, or a build-up of inventory.
- Average Receivable Collection Period
- The average receivable collection period has also shown an increasing trend, though less pronounced than the inventory processing period. It rose from 59 days in 2021 to 67 days in 2025. This suggests a lengthening time to collect payments from customers, potentially indicating changes in credit terms, customer payment behavior, or collection effectiveness.
- Operating Cycle
- The operating cycle, calculated as the sum of the average inventory processing period and the average receivable collection period, has increased consistently from 186 days in 2021 to 238 days in 2025. This lengthening operating cycle implies that the company is taking longer to convert its investments in inventory into cash. The combined effect of slower inventory turnover and receivable collection contributes to this extended cycle.
The observed trends suggest a potential need for review of inventory management practices and credit/collection policies. Further investigation into the underlying causes of these increases is warranted to assess their impact on liquidity and overall operational efficiency.
AI Ask an analyst for more
Average Payables Payment Period
| Dec 28, 2025 | Dec 29, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Payables turnover | 2.52 | 2.66 | 2.76 | 2.66 | 2.70 | |
| Short-term Activity Ratio (no. days) | ||||||
| Average payables payment period1 | 145 | 137 | 132 | 137 | 135 | |
| Benchmarks (no. days) | ||||||
| Average Payables Payment Period, Competitors2 | ||||||
| AbbVie Inc. | 72 | 64 | 66 | 61 | 60 | |
| Amgen Inc. | 72 | 54 | 69 | 90 | 77 | |
| Bristol-Myers Squibb Co. | 94 | 94 | 111 | 109 | 108 | |
| Danaher Corp. | 67 | 66 | 65 | 67 | 82 | |
| Eli Lilly & Co. | 178 | 140 | 134 | 106 | 83 | |
| Gilead Sciences Inc. | 42 | 49 | 31 | 58 | 39 | |
| Merck & Co. Inc. | 98 | 98 | 89 | 89 | 123 | |
| Pfizer Inc. | 119 | 115 | 98 | 72 | 66 | |
| Regeneron Pharmaceuticals Inc. | 163 | 146 | 122 | 138 | 84 | |
| Thermo Fisher Scientific Inc. | 50 | 45 | 41 | 48 | 53 | |
| Vertex Pharmaceuticals Inc. | 102 | 98 | 106 | 103 | 79 | |
| Average Payables Payment Period, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 98 | 90 | 86 | 85 | 86 | |
| Average Payables Payment Period, Industry | ||||||
| Health Care | 59 | 60 | 61 | 63 | 63 | |
Based on: 10-K (reporting date: 2025-12-28), 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 2.52 = 145
2 Click competitor name to see calculations.
The analysis reveals fluctuations in the company’s short-term payables management over the five-year period. Specifically, the payables turnover and average payables payment period exhibit distinct trends that warrant attention.
- Payables Turnover
- Payables turnover remained relatively stable between 2021 and 2023, fluctuating around 2.70. A slight decrease was observed in 2022, followed by a modest recovery in 2023. However, the ratio remained consistent at 2.66 in 2024 before declining to 2.52 in 2025. This suggests a gradual slowing in the rate at which the company pays its suppliers towards the end of the period.
- Average Payables Payment Period
- The average payables payment period experienced a slight increase from 135 days in 2021 to 137 days in 2022. It then decreased to 132 days in 2023, before returning to 137 days in 2024. A further increase to 145 days was recorded in 2025. This indicates a lengthening of the time taken to settle obligations to suppliers, particularly in the most recent year. The period remained within a narrow range for the first four years, with a more pronounced extension observed in 2025.
- Relationship between Ratios
- The observed trends in payables turnover and average payables payment period are inversely related, as expected. As payables turnover decreases, the average payment period increases, and vice versa. The decline in payables turnover in 2025, coupled with the corresponding increase in the average payment period, suggests the company may be strategically extending payment terms or experiencing challenges in maintaining consistent payment practices.
Overall, the company’s management of payables demonstrates a generally stable pattern with a potential shift towards slower payment processing in the final year of the observed period. Further investigation into the factors driving these changes may be beneficial.
AI Ask an analyst for more
Cash Conversion Cycle
| Dec 28, 2025 | Dec 29, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Average inventory processing period | 171 | 165 | 154 | 147 | 127 | |
| Average receivable collection period | 67 | 61 | 64 | 62 | 59 | |
| Average payables payment period | 145 | 137 | 132 | 137 | 135 | |
| Short-term Activity Ratio | ||||||
| Cash conversion cycle1 | 93 | 89 | 86 | 72 | 51 | |
| Benchmarks | ||||||
| Cash Conversion Cycle, Competitors2 | ||||||
| AbbVie Inc. | 102 | 97 | 82 | 85 | 70 | |
| Amgen Inc. | 216 | 222 | 441 | 273 | 228 | |
| Bristol-Myers Squibb Co. | 51 | 43 | 54 | 42 | 34 | |
| Danaher Corp. | 81 | 76 | 91 | 81 | 63 | |
| Eli Lilly & Co. | 375 | 278 | 261 | 219 | 197 | |
| Gilead Sciences Inc. | 124 | 107 | 132 | 104 | 111 | |
| Merck & Co. Inc. | 116 | 107 | 118 | 93 | 105 | |
| Pfizer Inc. | 192 | 173 | 120 | 63 | 92 | |
| Regeneron Pharmaceuticals Inc. | 539 | 586 | 555 | 584 | 345 | |
| Thermo Fisher Scientific Inc. | 98 | 97 | 101 | 97 | 115 | |
| Vertex Pharmaceuticals Inc. | 333 | 242 | 166 | 112 | 119 | |
| Cash Conversion Cycle, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 142 | 128 | 131 | 97 | 97 | |
| Cash Conversion Cycle, Industry | ||||||
| Health Care | 37 | 34 | 37 | 27 | 29 | |
Based on: 10-K (reporting date: 2025-12-28), 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= 171 + 67 – 145 = 93
2 Click competitor name to see calculations.
An examination of short-term operating activity reveals consistent trends across the observed period. The average inventory processing period, average receivable collection period, and average payables payment period all demonstrate directional movement, ultimately impacting the cash conversion cycle.
- Average Inventory Processing Period
- The average inventory processing period exhibits a consistent upward trend, increasing from 127 days in 2021 to 171 days in 2025. This indicates a lengthening of the time required to convert raw materials into finished goods and subsequently sell them. The rate of increase appears to be accelerating slightly in the later years.
- Average Receivable Collection Period
- The average receivable collection period generally increased from 59 days in 2021 to 67 days in 2025. While there was a slight decrease observed in 2024, the overall trend suggests a growing timeframe for collecting payments from customers. This could indicate evolving credit terms or potential inefficiencies in the collection process.
- Average Payables Payment Period
- The average payables payment period shows a more moderate increase, moving from 135 days in 2021 to 145 days in 2025. There was a slight dip in 2023, but the overall pattern suggests a lengthening of the time taken to settle obligations to suppliers. This could be a strategic decision to manage cash flow or a consequence of supplier negotiations.
- Cash Conversion Cycle
- The cash conversion cycle demonstrates a clear and consistent upward trend, rising from 51 days in 2021 to 93 days in 2025. This increase is a direct result of the combined effects of the lengthening inventory processing period and receivable collection period, partially offset by the increase in the payables payment period. A longer cash conversion cycle generally implies that the company is tying up more cash in its operations for extended periods, potentially impacting liquidity.
The observed trends suggest a gradual slowdown in the efficiency of working capital management. Continued monitoring of these ratios is recommended to assess the sustainability of these trends and their potential impact on overall financial performance.
AI Ask an analyst for more